Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > WOW...did Paul REALLY say this??? Exciting if he DID !!!

<< Previous

Bullboard Posts

Next >>

Comment by SPCEO1on Sep 28, 2022 6:52pm

189 Views

Post# 34993534

RE:WOW...did Paul REALLY say this??? Exciting if he DID !!!

We "think" we have the key is not the same as we "know" we have the key. CEO's are paid to be optimistic and Paul has said optimistic things about legacy drug sales and NASH previously that have not turned out to be accurate. So, yes, this is an encouraging comment but it needs to be viewed through an appropriately skeptical lens for now. Hopefully, he will soon be able to say "we know we have the key".